Molecular Imaging Clinical Trial
Official title:
An EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients Identification Strategy and Treatment Response Using Molecular Imaging
The investigators developed 18F-MPG as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status. And use 18F-MPG to monitor EGFR-TKIs and chemotherapy treatment efficiency.
The goal of investigators were to evaluate the use of 18F-MPG as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-MPG in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers. And the investigators want to evaluated the use of 18F-MPG in adult NSCLC patients with EGFR mutational status received non-treatment, EGFR-TKIs and chemotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02916329 -
In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule
|
N/A | |
| Completed |
NCT01944215 -
Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue
|
Phase 1 | |
| Recruiting |
NCT02916394 -
In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
|
N/A | |
| Active, not recruiting |
NCT03358589 -
Molecular Evaluation in Metastatic Breast Cancer
|
N/A | |
| Completed |
NCT03031522 -
EGFR Molecular Classification In Vivo
|
N/A | |
| Completed |
NCT03233243 -
Rosuvastatin Effect on Atherosclerotic Plaque Metabolism
|
Phase 4 | |
| Completed |
NCT02323217 -
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
|
Early Phase 1 | |
| Enrolling by invitation |
NCT05575765 -
Clinical Validation of Multimodal Digestive Endoscopy
|